Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers

Ilker Kahramanoglu

Status: Unknown

Conditions: Ovarian Neoplasms; Endometrial Neoplasms

Treatments: Diagnostic Test: TFF3, SFRP4, Romo1, NFKB

Study type: Observational

Funder types: Other

Identifiers

NCT03112733

TAB-2017-22506 (Other Grant/Funding Number)

83045809-604.01.02

Details and patient eligibility

About

This study evaluates the usefulness of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB as potential diagnostic and prognostic biomarkers in ovarian carcinoma.

Enrollment: 171 patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Primary diagnosis of epithelial ovarian carcinoma.

Exclusion criteria

• Patients with recurrence.
• Patients who received neoadjuvant chemotherapy or radiotherapy
• Presence of any secondary malignancy

Trial design

171 participants in 3 patient groups

Patients with ovarian carcinoma

Description:

Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.

Treatment:

Diagnostic Test: TFF3, SFRP4, Romo1, NFKB

Control group

Description:

Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.

Treatment:

Diagnostic Test: TFF3, SFRP4, Romo1, NFKB

Benign adnexal mass

Description:

Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.